Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. März 2013 13:12 ET | Quelle: Families of SMA

Families of SMA and Nationwide Children's Announce Multi-Million Dollar Award From NINDS to Advance CNS Gene Therapy for Spinal Muscular Atrophy

ELK GROVE VILLAGE, Ill., March 13, 2013 (GLOBE NEWSWIRE) -- Nationwide Children's Hospital (Columbus, OH) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announce the award of a...
03. Januar 2013 09:31 ET | Quelle: Families of SMA

Pfizer Licenses Families of Spinal Muscular Atrophy Quinazoline Drug Program From Repligen

ELK GROVE VILLAGE, Ill., Jan. 3, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance...
31. Dezember 2012 10:06 ET | Quelle: Families of SMA

Families of Spinal Muscular Atrophy Committed $2.5 Million to Funding SMA Research in 2012

ELK GROVE VILLAGE, Ill., Dec. 31, 2012 (GLOBE NEWSWIRE) -- Families of SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research...
28. Dezember 2012 10:07 ET | Quelle: Families of SMA

Families of Spinal Muscular Atrophy Awards $710,000 for Basic Research to Identify New and More Effective Approaches for SMA Therapies

ELK GROVE VILLAGE, Ill., Dec. 28, 2012 (GLOBE NEWSWIRE) -- Families of SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research...
26. September 2012 16:17 ET | Quelle: Families of SMA

Repligen Initiates Phase 1b Trial of RG3039 for Spinal Muscular Atrophy Licensed From Families of SMA

ELK GROVE VILLAGE, Ill., Sept. 26, 2012 (GLOBE NEWSWIRE) -- Repligen Corporation has initiated a Phase 1b clinical study of RG3039, a novel small molecule drug candidate for the potential treatment of...
07. Juni 2012 15:13 ET | Quelle: Families of SMA

Families of SMA Announces $1.4 Million Planned for Next Round of Spinal Muscular Atrophy Research Funding

ELK GROVE VILLAGE, Ill., June 7, 2012 (GLOBE NEWSWIRE) -- Families of Spinal Muscular Atrophy (FSMA) is dedicated to creating a treatment and cure for Spinal Muscular Atrophy (SMA) by funding and...
10. Mai 2012 15:44 ET | Quelle: Families of SMA

Families of SMA Announces $700,000 Funding for Novel Drug Program at Newly Created California Institute for Biomedical Research

ELK GROVE VILLAGE, Ill., May 10, 2012 (GLOBE NEWSWIRE) -- This new program will focus on optimizing small molecule drug candidates which increase the SMA back-up gene in order to make them ready for...
02. Mai 2012 16:14 ET | Quelle: Families of SMA

Families of SMA Awards New Funding to Advance a CNS Delivered Gene Therapy for Spinal Muscular Atrophy

ELK GROVE VILLAGE, Ill., May 2, 2012 (GLOBE NEWSWIRE) -- Families of SMA is pleased to announce the award of up to $750,000 for an important new grant to Dr. Brian Kaspar at Nationwide Children's...
25. April 2012 10:36 ET | Quelle: Families of SMA

Repligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA)

ELK GROVE VILLAGE, Ill., April 25, 2012 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety...
19. Januar 2012 10:07 ET | Quelle: Families of SMA

Update on the Spinal Muscular Atrophy Drug Development Pipeline From Families of SMA

ELK GROVE VILLAGE, Ill., Jan. 19, 2012 (GLOBE NEWSWIRE) -- Developing new therapies to treat and ultimately cure SMA is the driving force behind Families of SMA. To achieve this goal, Families of SMA...

Nächste Seite